The HIV Diagnosis Market is consolidated in nature due to the presence of a few large players. The prominent players in the market include Siemens AG (Germany), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S), Danaher Corporation (U.S.), Thermo-Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Becton, Dickinson and Company (U.S.), Hologic, Inc. (U.S.), Alere Inc. (U.S.), and Bio-Rad Laboratories (U.S.).
Siemens AG (Germany) was the largest player in the global HIV Diagnosis Market 2015. The company‘s laboratory diagnostics segment includes clinical chemistry, drug testing diagnostics, hematology, hemostasis, immunoassay, infectious disease testing, integrated chemistry, plasma proteins, and urinalysis products. Of these segments, immunoassay and infectious disease testing segment deal with the market. The company focuses on both organic and inorganic growth strategies to enhance its footprint in the market. The company introduced a number of advanced HIV diagnosis products in the market and also upgraded its existing solutions to expand its customer base and technological capabilities during the past years. For instance, in March 2014, Siemens released a software upgrade for the RAPIDComm Data Management System, a solution to centrally manage Siemens’ in vitro diagnosis analyzers and operators at the point-of-care. The company also adopted the strategy of expansions to maintain its position in this market. For example, December 2016, Siemens Healthineers invested USD 300 million in its Walpole, Massachusetts facility to manufacture ADVIA Centaur family of immunoassay instruments.
Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=66008285 Â
Roche Diagnostics (Switzerland) was the second-largest player in the global HIV Diagnosis Market in 2015. The company operates through two distinct segmentsâ€" Pharmaceuticals and Diagnostics. The company’s end users include hospitals, reference laboratories, patients, researchers, and physicians. Roche also holds a prominent position in the blood donor screening market and dominates the nucleic acid amplification (NAT) testing market. The company focuses on R&D activities for product launches to meet the needs of end users in the market. For example, in June 2016, Roche launched Cobas e 801 module which offers more than 100 immunoassays and a wide range of disease diagnostics. The company also focuses on increasing its presence in the emerging Asia-Pacific market. For instance, in November 2014, Roche launched a new facility in Suzhou, China. It is also taking necessary steps to increase its reputation in markets by various collaborations. In September 2014, Roche along with various other organizations launched a program for the viral load test.
Thermo Fisher Scientific Inc. (U.S.) was the third-largest player in the market in 2015. The company offers analytical instruments, equipment, reagents, consumables, and software services for research, discovery, analysis, diagnosis, and manufacturing. The company operates through four principal product segments, namely, Life Sciences Solutions, Analytical Technologies, Specialty Diagnostics, and Laboratory Products & Services. It provides immunoassays, nucleic acid amplification (NAT) controls, and quality controls for HIV diagnosis. The company has a significant global footprint owing to its strong sales and distribution network. The company focuses on product launches. For instance, in May 2015, Thermo Fisher launched iBind Flex Western device, working on the western blot technique for detection of infection. The company maintains its leadership position in the market with its strong portfolio of HIV diagnosis products and incessant efforts to develop innovative products by investing in R&D activities.
The key strategies followed by most companies in the HIV Diagnosis Market are product launches, expansions, agreements, partnerships, and collaborations. Product launches accounted for a share of 35.5% of the overall growth strategies adopted by players in the HIV Diagnosis Market. Roche Diagnostics (Switzerland), Merck KGaA (Germany), and Bio-Rad Laboratories (U.S.) are the leading manufacturing companies that adopted this strategy to expand their existing product portfolios and enhance their presence in the market.
Related Reports:
HIV Diagnosis Market by Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification, Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) - Global Forecast to 2021
The HIV Diagnosis Market is projected to reach USD 3.88 Billion by 2021 from USD 2.35 Billion in 2016, at a CAGR of 10.5% from 2016 to 2021.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
newsletter@marketsandmarkets.com
